Hyderabad, Telangana, India, February 2026 —Intas Pharmaceuticals has welcomed Saurabh Singhal as Deputy General Manager – Finance & Accounts, marking a strategic addition to its finance leadership team as the company continues its strong global growth trajectory.
In his new role, Saurabh Singhal will strengthen financial planning, governance, and performance management capabilities, supporting business expansion and operational excellence across the organization.
Prior to joining Intas Pharmaceuticals, Saurabh served as Associate Director at Bristol Myers Squibb, where he led FP&A for the Global Product Development and Supply team in Hyderabad, driving strategic financial planning, budgeting, forecasting, and stakeholder alignment in a highly regulated pharmaceutical environment.
Earlier, at PepsiCo, he led the Commercial FP&A team for the Australia Snacks Business, strengthening P&L oversight, commercial analytics, and financial performance management across the region.
He also spent over six years at Genpact, managing end-to-end FP&A for ANZ and Japan markets, overseeing financial transitions, reporting efficiency, and operational excellence initiatives for large-scale global portfolios.
In the early phase of his career, Saurabh held roles at Aptara Corp, Toyota Kirloskar Motor, and India Yamaha Motor Pvt. Ltd., building strong foundations in financial planning, operational strategy, dealer network analytics, and business process optimization. His professional journey began with hands-on engineering experience at MSC Ship Management Pvt. Ltd., bringing a unique blend of operational discipline and financial expertise to his leadership style.
About Intas Pharmaceuticals
Intas Pharmaceuticals is a leading multinational pharmaceutical formulation development, manufacturing, and marketing organization with operations in over 85 countries. Ranked 6th in the Indian pharmaceutical market, Intas is the largest privately owned Indian generic pharma company. With 17 advanced formulations, R&D, and distribution facilities globally and a workforce of over 23,000 employees, the company is recognized for its innovation-driven approach and strong global regulatory accreditations including USFDA, EMA, and MHRA. Intas continues to expand its presence across regulated markets with a robust pipeline of high-value generics, biosimilars, and NDDS products.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
